Japan Attention Deficit Hyperactivity Disorder Market Size & Outlook
Related Markets
Japan attention deficit hyperactivity disorder market highlights
- The Japan attention deficit hyperactivity disorder market generated a revenue of USD 249.4 million in 2023 and is expected to reach USD 362.3 million by 2030.
- The Japan market is expected to grow at a CAGR of 5.5% from 2024 to 2030.
- In terms of segment, stimulants was the largest revenue generating drug type in 2023.
- Non-stimulants is the most lucrative drug type segment registering the fastest growth during the forecast period.
Attention deficit hyperactivity disorder market data book summary
| Market revenue in 2023 | USD 249.4 million |
| Market revenue in 2030 | USD 362.3 million |
| Growth rate | 5.5% (CAGR from 2023 to 2030) |
| Largest segment | Stimulants |
| Fastest growing segment | Non-stimulants |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Stimulants, Non-stimulants |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 1.7% of the global attention deficit hyperactivity disorder market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan attention deficit hyperactivity disorder market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 341.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Attention Deficit Hyperactivity Disorder Market Scope
Attention Deficit Hyperactivity Disorder Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | View profile | 652 | 9715 Key West Avenue, Rockville, MD, United States, 20850 | https://www.supernus.com |
| NeuroSense Therapeutics Ltd | View profile | 16 | 11 HaMenofim Street, Building B, Herzliya, Israel, 4672562 | https://www.neurosense-tx.com |
| Vital KSK Holdings Inc | View profile | 5326 | 1-1-12 Tsurumaki, Setagaya-ku, Japan, 154-0016 | http://www.vitalksk.co.jp |
| Mallinckrodt PLC Ordinary Shares - New | View profile | 2700 | College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 | https://www.mallinckrodt.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Japan attention deficit hyperactivity disorder market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.89% in 2023. Horizon Databook has segmented the Japan attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
Four types of ADHD drugs are available in Japan: lisdexamfetamine dimesylate (Vyvanse), atomoxetine (Strattera), methylphenidate hydrochloride (Concerta), and guanfacine hydrochloride (Intuniv). Among these, methylphenidate hydrochloride is the most commonly prescribed ADHD medicine by physicians due to advantages such as avoiding clinical rebound, easy intake, low risk of abuse, and strong treatment adherence.
Moreover, Concerta and Strattera are the medications available for ADHD treatment in Japan. An individual needs to apply for the right documentation, Yakkan Shoumei (narcotic certificate), if more than 2.16 g of these stimulant drugs are imported. Vyvanse is not launched in Japan and can be imported as it is classified as general prescription medicine.
In Japan, the approved medications for treating ADHD are limited to methylphenidate (marketed as Ritalin and Concerta) and atomoxetine (marketed as Strattera). Access to these medications requires a prescription from a licensed physician, and their use for ADHD treatment is subject to strict regulations.
Reasons to subscribe to Japan attention deficit hyperactivity disorder market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan attention deficit hyperactivity disorder market databook
-
Our clientele includes a mix of attention deficit hyperactivity disorder market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into Japan attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan attention deficit hyperactivity disorder market size, by drug type, 2018-2030 (US$M)
Japan Attention Deficit Hyperactivity Disorder Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
